KAPA KAPA
Company Profile ↓Company Overview
KAPA (KAPA) is a publicly traded company listed on with a market capitalization of $6.87M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -65.08% |
| 6 Months: | -50.00% |
| 3 Months: | -40.54% |
| 1 Month: | -8.33% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.07 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 83.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -287.00K | -287.00K | -222.00K | -383.00K | -1.27M | -1.46M | -1.44M | -1.69M |
| Net Income | -312.00K | -323.00K | -253.00K | -1.05M | -1.26M | -1.42M | -1.40M | -1.65M |
| Diluted EPS | -0.03 | -0.03 | -0.02 | -0.10 | -0.08 | -0.08 | -0.07 | -0.08 |
| R&D Expense | 33.00K | 165.00K | 63.00K | 14.00K | 493.00K | 496.00K | 608.00K | 684.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -1.71M | -2.34M | -5.57M |
| Net Income | -1.81M | -2.60M | -5.45M |
| Diluted EPS | -0.17 | -0.23 | -0.30 |
| R&D Expense | 82.00K | 414.00K | 2.13M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.04M | 965.00K | 5.77M | 6.54M |
| Current Assets | - | 437.00K | 101.00K | 4.17M | 5.39M |
| Cash & Equivalents | - | 437.00K | 93.00K | 1.27M | 4.49M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 2.21M | 3.04M | 992.00K | 199.00K |
| Current Liabilities | - | 1.63M | 2.40M | 992.00K | 199.00K |
| Long Term Debt | - | 582.00K | 638.00K | - | - |
| Total Debt | 380.00K | 582.00K | 638.00K | - | - |
| Total Equity | - | -1.18M | -2.08M | 4.78M | 6.34M |
| Shares Outstanding | - | 12.84M | 12.84M | 13.74M | 20.82M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 81.00K | -3.96M | -3.44M |
| Financing Cash Flow | -425.00K | 5.13M | 6.66M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 87.2% | -54.5% | -85.9% |
| ROCE % | 119.0% | -49.1% | -87.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KAPA
All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPU3FqNjZFRGJEelBuRkRyNzZzTzhWbWVwVk5vSF9aSHJjbFN5YkFvRkNLR2FyZ2Q2T2VnbjN1am5Lc1EzQ0VLLUlJd00wNllycEFpU184N1NIOG4tWXpra0JfaHZnb3dYS29ud1lORjFYS1U2a3MyU1ByZG1ZM2kwN2Uta3Y3TlhLeXFZRk…
New Kairos Pharma lung cancer drug targets $16.2B market - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQZnk0VlQyemlBVXppWVFMYUhLeVZZbl9GejQwbG1zWl9GRWk4TThJZm5MRm1qeWNheElUdjR6OTd4aTB3WmtrQ19FeGE2VkhjRERtV241QTFYVW5GODlsYWpySE8tUjVhbU1kWHRNZGJVcHZ1aGxyN0dkZS1GNzU4LTZyLS10cS1vVHdTSm…
Kairos Pharma Ltd (KAPA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE8zSFN1ZDBpdEFBNkVEbTlYUzRKaDd5SG9KNExNLVVCd1pJQXFkVVhta09Sam5mc3Fkb1F3ZGxrSC1MajRmTklGT2FMWElQQnQ3UUVhTThScHlxVjBoNGg1UzV1eVVFN1k?oc=5" target="_blank">Kairos Pharma Ltd (KAPA) Tec…
Maxim Group Maintains Kairos Pharma(KAPA.US) With Buy Rating - Moomoo
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPS3VoSGFJeU1ZMDBqWkNFRDk2TXBtRVFfVlprOTFOZlNsNmFsNmZyalhtZk9zMzc3Y29ma2J1dzJQTUlEMXItcGYtWkJ2cTJXU0h3OWRYYzN4ZzNEcnk3TkgwWTJFa3hINlpySmY5TEVaMEVFeEhQWGIxMGtNbXRCaDdtRW45TWRjcFJVcT…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5tRFczWnVJbjFMREoxdFVDd2hncnk3VThYYVZtMGo0U2M3alE5OW5BcmRzNWlRUDAwdEhWemU1YTM1ZnVJblFkdHpLWGYtNXpi?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Kairos Pharma Sees Significant Decline as Stock Approaches Key Support Level - Money Flow - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOeno5T0RlZWpsU0ZUY2xtRVlXVW1GSUxsTXRnSTRmWklzT0RMakQ3Q05kSkF4MWJRa2VzTmVDbWVRR2RteV9SQUlNYmY3NWpTWkRXNjE5MUdybDBkcXk3VzViQWlPUEItcHdaUlJRVWVnSWE2R1J4UHNGdFpQZ0xKSU1oZVc4cXdoMmxXTU…
KAPA — Frequently Asked Questions
What is the current share price of KAPA?
As of 2026-08-05 17:25 PDT, KAPA trades at $0.33 on NASDAQ/NYSE. Its 52-week range is $0.28 to $1.97.
What is the market capitalisation of KAPA?
KAPA has a market capitalisation of $6.87M on NASDAQ/NYSE.
What is the P/E ratio of KAPA?
KAPA trades at a trailing price-to-earnings (P/E) ratio of -1.10. Its price-to-book (P/B) ratio is 1.08.
What is the return on equity (ROE) of KAPA?
KAPA has a return on equity (ROE) of -85.90%. Its return on capital employed (ROCE) is -87.87%.
Is KAPA a good stock to buy?
This page provides a data-driven analysis of KAPA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.